Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Upadacitinib (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms U-Accomplish
- Sponsors AbbVie; AbbVie Germany
- 27 Nov 2023 Results from NCT02819635; NCT03653026, assessing the efficacy and safety of upadacitinib in patients with moderate-to-severe ulcerative colitis following 16-week extended induction therapy, and 52-week maintenance therapy in patients achieving clinical response after 16-week extended induction therapy , published in the Alimentary Pharmacology and Therapeutics
- 02 Nov 2023 Results of post hoc , pooled analysis from NCT02819635 and NCT03653026; evaluating the effects of upadacitinib on fatigue, bowel urgency, and abdominal pain in patients with moderately to severely active ulcerative colitis, published in the Inflammatory Bowel Diseases
- 17 Oct 2023 Results of post hoc , pooled analysis from U-ACHIEVE and U-ACCOMPLISH, analyzing Achievement of Long-Term Treatment Goals with Upadacitinib , presented at the 31st United European Gastroenterology Week